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Genotyping Sleep Disorders Patients 
ObjectiveaaThe genetic susceptibility factors underlying sleep disorders might help us pre-
dict prognoses and responses to treatment. Several candidate polymorphisms for sleep disor-
ders have been proposed, but there has as yet inadequate replication or validation that the can-
didates may be useful in the clinical setting. 
MethodsaaTo assess the validity of several candidate associations, we obtained saliva deoxy-
ribonucleic acid (DNA) samples and clinical information from 360 consenting research par-
ticipants who were undergoing clinical polysomnograms. Ten single nucleotide polymor-
phisms (SNPs) were genotyped. These were thought to be related to depression, circadian sleep 
disorders, sleep apnea, restless legs syndrome (RLS), excessive sleepiness, or to slow waves 
in sleep.
ResultsaaWith multivariate generalized linear models, the association of TEF rs738499 with 
depressive symptoms was confirmed. Equivocal statistical evidence of association of rs1801260 
(the C3111T SNP in the CLOCK gene) with morningness/eveningness and an association 
of Apolipoprotein E (APOE) rs429358 with the Epworth Sleepiness Scale (ESS) were ob-
tained, but these associations were not strong enough to be of clinical value by themselves. Pre-
dicted association of SNPs with sleep apnea, RLS, and slow wave sleep were not confirmed. 
ConclusionaaThe SNPs tested would not, by themselves, be of use for clinical genotyping 
in a sleep clinic.   Psychiatry Investig 2010;7:36-42
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Introduction
In a sleep clinic, the causes of our patients’ distress can be complex and obscure. We might 
better understand prognosis and likely responses to treatment interventions when the etiolo-
gies can be identified. For example, a patient with excessive sleepiness may have both sleep 
apnea and depressive symptoms, both of which may have genetic components. A patient com-
plaining of insomnia may have genetically-mediated delayed sleep phase disorder and rest-
less legs combined with a cognitive-behavioral disturbance. Since reported sleep duration 
appears to be as much as 50% heritable, both short sleep complaints and long sleep compl-
aints may arise in large part from genetic susceptibilities.
1-4 Recognizing genetic susceptibil-
ities for depression, delayed sleep phase, restless legs or short sleep, for example, might help 
confirm diagnostic formulations and anticipate the responses to treatment options.
With the rapid pace of genomic discoveries, many research groups and not a few corpora-
tions are exploring the idea that genotyping individuals may help guide their health care. With 
the long-term goal of applying genotyping to our care of sleep clinic patients, we have begun 
to genotype patient volunteers on a research basis when they are undergoing clinical polysom-
nograms. We hoped to validate the association of candidate sleep disorder susceptibility fac-
tors with various symptom phenotypes, and to assess the extent to which genotypes might be-
come helpful in identifying the etiologies of our patients’ complaints.
To date, only a limited number of genetic polymorphisms have been suggested as causes 
of the diverse sleep disorders. The alleles of 4 single nucleotide polymorphisms (SNPs) 
online © ML CommDF Kripke et al. 
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possibly related to circadian rhythms and affective disorders, 
3 SNPs possibly related to sleep apnea, 2 SNPs possibly re-
lated to restless legs syndrome (RLS) or periodic limb move-
ments in sleep (PLMS), and 1 SNP possibly related to slow 
wave sleep were identified (Table 1). These 10 SNPs were se-
lected from the larger number with previously-reported sleep 
associations based on ease of genotyping and the predicted 
likelihood of association in our Clinic sample. 
Our prospective hypotheses were as follows. Based on a 
finding among sib pairs with a proband with early-onset recur-
rent unipolar major depression,
5 it was prospectively predict-
ed that the common T allele of rs738499 of TEF (a gene par-
ticipating in circadian system feedback loops) would be as-
sociated with the QIDS-SR measure of depressed mood. Like-
wise, based on prior evidence that rs2314339 (a SNP in NR1D1 
or Rev-erb-alpha, a component of circadian system feedback 
loops) was associated with bipolar disorder, it was predicted 
that rs2314339 would be associated with the QIDS-SR, even 
though rs2314339 had not been significantly associated with 
unipolar major depression in the prior study.
5 Because of the 
evident functional role of circadian SNPs, it was also prospec-
tively predicted that the BALM morningness-eveningness sc-
ale would be associated with rs738499, rs2314339, the Phe-
876Leu amino-acid changing SNP in PER2
6 and rs1801260 
(the C3111T SNP in the CLOCK gene previously reported to 
be related to morningness-eveningness and to insomnia).
7 Fur-
ther, based on previous reports, it was prospectively predict-
ed that sleep apnea might be associated with rs405509 and 
rs429358 [SNPs related to the Apolipoprotein E 4 (APOE 4) ge-
notype] and rs1800629, a -308 tumor necrotic factor α (TNF 
α) promoter polymorphism which influences TNFα expres-
sion.
8-13 Also, rs5751876 in ADORA2A, the A2A adenosine 
receptor, is associated with higher electroencephalography 
(EEG) amplitudes especially below 5 Hz regardless of sleep 
or wake, so we predicted rs5751876 would be associated with 
the slow wave sleep percentage or with total sleep time (TST).
14 
We further predicted that MEIS1 rs12469063 and MAP2K5 
rs 1026732 would be associated with restless legs frequency, 
the 4 essential questions for diagnosis of RLS, and the poly-
somnographic periodic limb movement index.
15-17 Several sec-
ondary hypotheses were also examined.
Methods
Consent and questionnaire
When a clinical research staff member was available and 
the clinical context permitted, patients arriving at our sleep 
laboratory for clinical recordings or who had recently under-
gone sleep recordings were invited to participate in our ge-
netics research program. First, the study was explained. Then 
a signed consent approved by the Scripps Institutional Re-
view Board was obtained. If it had not already been complet-
ed as part of our clinical patient intake procedure, a compre-
hensive sleep questionnaire was completed (form can be re-
quested from the authors). The questionnaire asked about 
habitual bedtimes, falling-asleep times, wake-up times, and 
uptimes both on weekdays and weekends. It included dozens 
of multiple-choice questions about the frequency and severity 
of various sleep symptoms. Embedded in the questionnaire 
were the BALM morningness-eveningness scale (a simplified-
language abbreviation of the Horne-Östberg morningness-
eveningness scale
18 with which it correlates r=0.96), the QI-
DS-SR (a modern self-report depression rating scale which 
has been validated against the Hamilton Depression Rating 
Scale and against DSM-IV major depression diagnoses),
19,20 
and the Epworth Sleepiness Scale (ESS) (a widely used rating 
of daytime sleepiness),
21 along with the four questions essen-
tial for a diagnosis of RLS, often associated with PLMS.
22-24
Polysomnogram 
Participants underwent standard clinical polysomnograms 
in our sleep laboratory using Compumedics Profusion PSG 
2.10.0.131 software on a Compumedics E Series platform. 
Recordings were scored according to the current criteria of 
the American Academy of Sleep Medicine. In 59% of the re-
cordings, the patient was awakened after sleep apnea was 
detected, and nasal continuous positive airway pressure (CPAP 
treatment) was titrated during the latter part of the recording. 
Table 1. Gene targets with observed genotype frequencies
Gene TEF NR1D1 TNFα CLOCK PER2
SNP rs738499 rs2314339 rs1800629 rs1801260 Phe876Leu
6
Genotypes GG : TG : TT CC : CT : TT AA : GA : GG CC : TC : TT AA : AG
N 21 : 145 : 190 252 : 93 : 14 4 : 98 : 257 22 : 140 : 196 345 : 14
SNP rs405509 rs429358 rs5751876 rs12469063  rs1026732
Genotypes GG : GT : TT CC : TC : TT CC : CT : TT AA : AG : GG GG : GA : AA
Gene APOE APOE ADORA2A MEIS1 MAP2K5
N 99 : 181 : 79 3 : 98 : 258 125 : 165 : 69 212 : 125 : 22 124 : 165 : 40
Each assayed single nucleotide polymorphism (SNP) is identified by an “rs” number, which links to detailed documentation available, 
e.g., through the SNP data base provided by NCBI Entrez at http://www.ncbi.nlm.nih.gov/sites/entrez or the UCSC Genome Browser 
available at http://www.genome.ucsc.edu/cgi-bin/hgGateway38  Psychiatry Investig 2010;7:36-42
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In these split night studies, scoring of the polysomnograms 
was divided into two portions. Phenotypes were computed 
from the first portion of split recordings unmasked by CPAP, 
except in 10 recordings where there was so little sleep in the 
first portion that use of the CPAP portion appeared more rep-
resentative.
DNA collection
The participants were asked to provide about 2 cc of saliva 
in an Oragene deoxyribonucleic acid (DNA) Self-collection 
Kit (DNA Genotek, Inc., Ottawa, Ontario, Canada), used ac-
cording to the manufacturer’s directions. DNA was stored with 
preservative in the Oragene kits at room temperature until it 
could be extracted and purified according to the manufactur-
er’s protocol, producing an average of 80-120 mcg. of purified 
DNA. DNA was then frozen in split samples for further study. 
Phenotype determination 
In accordance with the consent granted, polysomnographic 
data, clinical diagnoses from multiple visits, and clinical re-
ferrals were compiled with coded identifiers in research data 
bases. For this study, the following 10 quantitative phenotypic 
traits were derived from the data bases: 1) ESS score for day-
time sleepiness,
21 2) BALM score for the morningness-eve-
ningness circadian trait,
18 3) QIDS-SR score for current depres-
sion,
19,20 4) number of 4 essential RLS complaints (restless 
legs essential features) answered affirmative,
23 5) answer on 
a 6-point scale of frequency of “a feeling of restless legs”, 6) 
polysomnographic TST in minutes, 7) polysomnographic slow 
wave sleep percentage, i.e., stage 3%+stage 4%, 8) polysom-
nographic periodic leg movement index, 9) polysomnograph-
ic apnea-hypopnea index (AHI), 10) a global score summa-
rizing the extent of clinician documentation of an obstructive 
sleep apnea diagnosis. This apnea diagnostic score was com-
piled from arbitrary weights for the number of visits and inter-
val of months over which an apnea diagnosis was recorded 
clinically; likewise the number of visits, interval, and stated con-
fidence in which a separate research diagnosis of obstructive 
apnea was recorded; whether a referral for CPAP or mandib-
ular advancement device treatment was recorded; the poly-
somnographic AHI (if 15 or more) and the index of oximetry 
desaturations of ≥4% (if 15 or more per hour). Each of these 
phenotypic traits reflecting a manifestation of sleep disorders 
could then be examined for its association with particular 
genotypes. 
Assays 
DNA was genotyped for the first 360 participants at the 
DNA Core Laboratory of the Molecular and Experimental 
Medicine division of the Scripps Research Institute, using al-
lele-specific oligonucleotide hybridization.
25 A single subject 
was dropped for inadequate DNA quantity. Technical diffi-
culties assaying certain SNPs and expense limited this report to 
10 SNPs from a much larger number which might have been 
of interest (Table 1).
Statistics
The quantitative phenotypes were tested as dependent vari-
ables in multivariate generalized linear models, using as in-
dependent predictors the participant’s age (continuous), gen-
der (binary), race (self-reported and recoded as white or non-
white), and the genotypes. Additive, dominant, and recessive 
models were tested in these analyses when applicable. For 
the dominant and recessive models, each SNP was modeled as 
a dichotomous variable with one genotype (either dominant or 
recessive) chosen as the reference group, and the other two 
genotypes combined into one category. For the additive mod-
el, the number of dominant alleles was used as the variable. 
No adjustments for multiple comparisons were conducted in 
the analyses, since the primary analyses tested independent 
prospective hypotheses. Analyses were implemented in Sys-
tat V.12 (Systat Software, Inc., Chicago, IL, USA).
Results
The 359 participants ranged from age 21 to 92 years, with 
a mean age of 57.4 (±standard deviation 13.9) years. Partici-
pants were 33% women and 67% men. The sample was 90% 
White by self-report. The global obstructive apnea scores rang-
ed from 3 to 94 with a mean of 25. Apnea global scores indi-
cated some clinical consideration of an apnea diagnosis for 
every patient, though in many cases, a clinician might have 
coded an apnea diagnosis based on clinical supposition which 
later was not confirmed by polysomnography. The number 
of times clinical and research diagnoses of apnea were record-
ed, treatment referrals, AHIs, and oxygen desaturation indices 
(ODIs) (4% ODIs) contributed 48%, 15%, 10%, 17%, and 10% 
respectively to the global apnea scores. In 10% of participants, 
sleep apnea (any kind) was not a first diagnosis, e.g., primary 
diagnoses of insomnia, delayed sleep phase disorder, rapid eye 
movement behavior disorder, and narcolepsy. Polysomnogra-
phically, 22% had an AHI of less than 5 (suggesting no clini-
cally significant sleep apnea), and only 47% had an AHI of gr-
eater than 15 (a commonly-used threshold indicating when CP-
AP treatment is indicated.) Parenthetically, 43% had ODI<5. 
In only 10 of the recordings was it necessary to utilize the CPAP 
titration portion of a split PSG for analysis because there was 
insufficient sleep in the first part. Of these 10 recordings during 
CPAP, 7 had an AHI<5, but presumably the CPAP suppressed 
the AHI as compared to what would be observed without CP-
AP. Partly because of the split night procedures, the mean TST 
for the recording segments utilized was only 253 minutes.
Examining the association of the QIDS-SR depression 
score with TEF rs738499 as well as age, gender, and race as DF Kripke et al. 
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independent control variables, the overall regression yielded 
R
2=0.06, with all independent variables being significant 
(Table 2). The adjusted mean QIDS-SR was 6.5±standard 
error (SE) 0.9 for the GG rs738499 genotype, 6.9±SE 0.4 for 
the GT genotype, and 7.9±SE 0.3 for the TT genotype. Con-
trolling for age, gender, and race, the rs738499 T allele being 
present or absent was significantly associated with the QIDS-
SR score with R
2=0.03 and p=0.025, whereas the significance 
was p=0.008 for an additive model for the T allele, e.g., TT> 
TG>GG, where T is the more common allele. Since this as-
sociation had been prospectively predicted as the highest pri-
ority hypothesis, this association was considered significant. 
The NR1D1 SNP genotype was not significantly related to the 
QIDS-SR.
Although with CLOCK rs1801260, the BALM score aver-
aged 33.8±SE 1.9 in the CC genotypes, compared to 36.8±SE 
0.8 in the TC genotypes and 37.4±SE 0.7 in the TT geno-
types, the probability of association was only p=0.071, two-
tailed. This result might be considered equivocally signifi-
cant by one-tailed criteria, considering that the association 
and its direction (less morningness with the C allele) was pre-
dicted in advance based on prior work.
7 The NR1D1, TEF, 
and PER2 SNP genotypes were not significantly associated 
with the BALM score.
The predictions that TNFα rs1800629 and the APOE SNPs 
rs405509 and rs429358 would be associated with the AHI or 
with the global apnea score were not confirmed. However, in 
rs429358, the more common T allele was weakly associated 
with the ESS (Table 3), an association which had not been 
prospectively predicted. The other two SNPs, rs405509 and 
rs1800629, were not associated with the ESS. 
MEIS1 rs12469063 and MAP2K5 rs1026732 were not sig-
nificantly associated with the four diagnostic questions for RLS 
syndrome, with the reported frequency of “restless legs,” or 
with the polysomnographic periodic leg movement index. AD-
ORA2A rs5751876 was not significantly associated with poly-
somnographic TST nor with the slow wave sleep percentage.
In retrospective Post Hoc computations (which do not meet 
Bonferroni significance criteria for multiple testing), the T 
allele of TEF rs738499 was associated with the percentage 
of slow wave sleep (sleep stages 3 and 4), controlling for co-
variates of gender, age, and race (p<0.05). Similarly, EEG 
TST was associated with the C allele of CLOCK rs1801260 
(p=0.04) and the A allele of TNFα rs1800629 (p<0.025). Se-
lecting on those roughly 50% of participants with AHI<15, 
to minimize confounding with apnea, the PLMI was greater 
among those with the C allele of CLOCK rs1801260 (p< 
0.05), the number of the 4 RLS questions answered affirma-
tively was associated both with the A allele of MEIS1 rs 
12469063 (p<0.01, but not the predicted direction of associa-
tion) and with the T allele of TEF rs738499 (p<0.025), and 
the T allele of NR1D1 rs2314339 was positively associated 
with the reported frequency of a feeling of restless legs. No 
such associations were noted in the group with AHI≥15. 
Moreover, no such associations were noted when groups an-
swering the four RLS questions were dichotomized into those 
answer yes to all 4 or <4. 
Discussion
The genomic revolution is a work in progress, providing 
remarkable developments in methodology, exciting new dis-
coveries, and many disappointments and frustrations. For ex-
ample, the whole genome association chips have led to nu-
merous new discoveries but also to an appreciation that tens 
of thousands of subjects may be needed to locate the relevant 
Table 3. Association of the ESS with APOE rs429358 genotype, age, gender, and race
Source SS df Mean squares F-ratio p-value
APOE rs429358 159.552 002 079.776 3.332 0.037
Age 0.493 001 000.493 0.021 0.886
Gender 79.127 001 079.127 3.305 0.070
Race 230.436 001 230.436 9.624 0.002
Error 8,428.494 352 023.945
ESS: Epworth Sleepiness Scale
Table 2. Association of QIDS-SR with the TEF rs738799 genotype, age, gender, and race
Source SS df Mean squares F-ratio p-value
TEF rs738799 107.140 002 53.570 3.709 0.025
Age 70.652 001 70.652 4.892 0.028
Gender 61.431 001 61.431 4.253 0.040
Race 69.475 001 69.475 4.810 0.029
Error 5,040.868 349 14.44440  Psychiatry Investig 2010;7:36-42
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polymorphisms for complex disorders such as hypertension 
and diabetes, in which dozens or hundreds of variants may 
make small contributions to the phenotype.
26-28 Few of the as-
sociations demonstrated by this new technology explain more 
than a small fraction of each disease phenotype,
29 perhaps 
because many rare variants rather than a few common vari-
ants produce the genetic susceptibility. Distinguished observ-
ers have argued that there is little value for individual patients 
in current genotyping methods for most major disorders.
27 
Research in a patient sample undergoing clinical polysom-
nograms had the strength of relevance to patients for whom 
diagnostic determination and treatment choice was a high 
priority. Another advantage was clinical support for the diag-
nostic assessment. Serious limitations of this approach includ-
ed lack of consistent diagnostic criteria, since the national 
standards changed during the study, diagnostic uncertainty or 
multiple diagnoses in many instances, and the variability in 
the portion of the polysomnogram which could be utilized if 
split-night CPAP titration procedures were begun. Also, even 
without CPAP titrations, there is considerable night-to-night 
variability in polysomnographic measures such as the peri-
odic leg movement index.
30 With a larger patient sample, we 
might have been able to demonstrate more significant associ-
ations of genotypes with sleep phenotypes, but the lower the 
attributable risk of an association and the larger the sample 
needed to detect association with a genotype, the less the clini-
cal value of genotype association will be. In the prospectively 
predicted results, none of the associations were strong enough 
to be considered statistically conclusive without further rep-
lication. Of the post-hoc analyses, none of the nominal find-
ings would have been significant after correction for multiple 
testing, so they should merely be considered hypothetical re-
lationships needing further replication. 
Because depression is commonly comorbid with sleep ap-
nea, insomnia, restless legs, and narcolepsy, depression is very 
commonly seen among Sleep Clinic patients. A large compo-
nent of depression is hereditary,
31 so depression might be one 
of the sleep-disturbing disorders most identifiable by genetic 
means. Unfortunately, the genetic basis of depression has 
proved surprisingly elusive, as indicated by the disappointing 
results of the GAIN whole genome association study, which 
used over 3,500 subjects.
32 Our result replicating an associa-
tion of TEF rs738799 with a quantitative trait of depression 
was therefore of considerable scientific interest, though the 
level of statistical confidence even combining this and the ear-
lier study
5 was not so great as to make further replication un-
necessary. It is possible that rs738799 is not the functional 
SNP associated with depression, in which case, a search for 
the functional SNP or a group of functionally significant poly-
morphisms might yield an association of greater magnitude. 
By itself, rs738799 might not display sufficient association 
with depression to make its identification valuable for pre-
dicting the usefulness of antidepressant treatment. 
Remarkable new findings with RLS and PLMS may prom-
ise that genotyping could identify a larger proportion of the 
risk for these disorders than most whole genome association 
results for other disorders.
15,33,34 To our surprise, we were not 
able to confirm that genotyping identified a useful proportion 
of the risk for restless legs or PLMS, but we were only able 
to genotype two of the several SNPs for which the strongest 
associations had been reported, and MEIS1 rs12469063 was 
technically difficult to genotype in our assay.
15,33 Part of the 
explanation for our failure to demonstrate association may 
be the limited positive predictive value of the four criterion 
questions which we used to identify restless legs.
23,35 Another 
problem may be the interference of sleep apnea with recog-
nizing RLS, since there was a nominally significant associa-
tion of the RLS questions with MEIS1 rs12469063 among 
those participants with lower AHI scores. The retrospective 
evidence for nominal association with PLMI or restless legs 
symptoms with three circadian SNPs (CLOCK rs1801260, 
TEF rs738499, and NR1D1 rs2314339), consistent with the 
strong circadian modulation of restless legs symptoms, might 
be explained by regulation of dopamine by MAOA, which is 
under control of the circadian network.
36,37 Circadian system 
genetic feedback loops regulate the expression and activity 
of the CLOCK-ARNTL heterodimer, which binds to an e-box 
promoter site on the MAOA gene. The greater the expression 
of MAOA, the faster the degredation of dopamine, thus reg-
ulating dopaminergic mediation of restless legs symptoms.
There is as yet little knowledge of the genetic factors in 
sleep apnea. We could not confirm reports that TNFα and 
APOE are substantial risk factors for sleep apnea, as some 
reports have suggested,
8-13 but our results support the recent 
meta-analysis which concluded that APOE is not associated 
with sleep apnea.
38 The SNP rs405509 does not fully define 
the APOE4 haplotype, but it is very highly associated with 
Alzheimer’s Disease.
39 As we expand our sample, we will have 
more participants with no indication of sleep apnea, which may 
make the discrimination of sleep apnea syndrome stronger. 
However, since half of the participants had an AHI<15, the 
sample may have been well-balanced for detecting polymor-
phisms associated with apnea in need of treatment. We found 
statistically equivocal evidence that an APOE variant is asso-
ciated with sleepiness, but the possible association noted was 
too weak to be of any current practical value. Likewise, we 
have as yet little knowledge of the genetic factors determin-
ing sleep duration, despite its considerable heritability.
1-4
 In ADORA2, rs5751876 had been reported to influence 
EEG slow wave amplitude,
14 but it had not been reported to in-
fluence either TST or the slow wave sleep percentage. We test-
ed the novel hypotheses that a polymorphism which increas-
es EEG slow waves should increase the percentage of slow 
wave sleep scored and perhaps the TST, but could not confirm DF Kripke et al. 
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these hypotheses. The nominal associations of TEF rs738499 
with slow wave sleep percentage and of CLOCK rs1801260 
and TNFα rs1800629 with TST should not be regarded as 
conclusive findings unless they can be replicated. Patel et al.
40 
found that TNFα concentrations were higher in the blood of 
those reporting longer habitual sleep, but TNFα was associ-
ated with shorter objective PSG durations.
Examination of four SNPs of the circadian system provid-
ed an equivocal confirmation of the influence of rs1801260 in 
CLOCK, which did not quite satisfy the strictest significance 
criteria. This previously-reported association has been contro-
versial,
7,41-45 but the current results tend to support a weak as-
sociation. Linkage disequilibrium extends throughout the large 
CLOCK gene, so this SNP may be linked to the true functional 
SNP only in certain populations. Elsewhere, we have reported 
SNPs with a stronger association with the BALM scale.
5 We 
believe that as knowledge of circadian polymorphisms 
grows, it may be possible to better recognize the genetic cir-
cadian component of sleep disorders. 
This study replicated some reported associations of SNP 
polymorphisms with sleep phenotypes, found other reported 
associations not to be replicable, and contributed preliminary 
suggestions of some new associations. These results add to the 
body of knowledge of genetic polymorphisms which influ-
ence sleep. Significance of associations of some of these 10 
SNPs with phenotypes might be more conclusively demonst-
rated with larger samples, e.g., the association of the CLOCK 
SNP rs1801260 with the BALM, but if more subjects are 
needed, such associations are likely to explain too little pheno-
typic variance to be of clinical value by themselves. Our sam-
ple was larger than that of most of the papers which originally 
reported the associations examined. Because so many asso-
ciations with phenotypes in genetics have proven nonrepli-
cable,
46,47 failures to replicate associations are informative, as 
a minimum for highlighting the modesty of effect sizes.
The discovery of the genetic factors in sleep disorders is 
still in its infancy. New reports of polymorphisms associated 
with sleep disorders are appearing. For example, our assays 
were performed before the very recent report relating poly-
morphisms in a T cell receptor to narcolepsy,
34 and there are 
many other interesting SNPs we have not yet examined. As 
the knowledge base expands, many more polymorphisms 
worth testing will emerge, and more extensive genotyping 
will become progressively more economically practical as the 
technology develops. In conditions with complex genetic sus-
ceptibility factors, it may become possible to identify a useful 
amount of genetic susceptibility by assaying much larger 
numbers of markers. The advancement of genetic knowledge 
to assist sleep disorders treatment depends on the foresighted 
collection of still larger DNA samples of several homogeneous 
racial groups, along with reliable data bases of phenotypes. 
We remain hopeful that future discoveries will make geno-
typing useful for the sleep clinician.
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